In addition, an in vivo tumor xenograft study reveals that inhibiting WISP-3 expression reduces the expression of the vessel markers CD31 and VEGF-A, indicating that WISP-3 enhances angiogenesis in vivo [18]. The gene discussed is VEGFA; the disease is neoplasm.